Skip to main content
. Author manuscript; available in PMC: 2020 Nov 4.
Published in final edited form as: Stem Cells. 2014 May;32(5):1361–1366. doi: 10.1002/stem.1635

Figure 1.

Figure 1.

Loss of p15Ink4b accelerates development of myeloid neoplasms in mice. Complete blood counts from p15Ink4bfl/flNHD13 mice aged 3–4 months. (A): Complete blood counts from p15Ink4bfl/flNHD13 mice aged 3–4 months. Hb levels were significantly decreased in the p15Ink4bfl/flNHD13 group as compared to WT animals (p15Ink4bwt/wt-LysMCre), *, p = .0024. The WBCs were significantly decreased in the NHD13 group (*, p = .001) and significantly increased in the p15Ink4bfl/fl-LysMCre animals, *, p = .01, as compared to WT. The monocyte count was significantly increased in the p15Ink4bfl/fl-LysMCre group as compared to WT, *, p = .008. (B): Survival of p15Ink4bfl/flNHD13 animals is significantly shorter as compared to the animals in NHD13 group, *, p = .0007. (C): Classification of hematologic malignancies in p15Ink4bfl/flNHD13 mice. The number of animals and the median survival among the animals diagnosed with the same malignancy are shown. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; Hb, hemoglobin; MDS, myelodysplastic syndromes; MPD, myeloproliferative disease; NHD13, Nup98-HoxD13; WBC, white blood cell count; WT, wild type.